Since the published literature is establishing a clear relationship between PLD1 and mTOR, further investigations are required to explore the inhibition of PLD1 for mTOR-driven malignancies, as well as the inclusion of PLD1 inhibitors in HNSCC clinical trials. The gene discussed is PLD1; the disease is head and neck squamous cell carcinoma.